Somatostatin receptor scintigraphy in thoracic diseases

P. Ameril, F. Gatto, M. Arvigo, G. Villa, E. Resmini, F. Minuto, G. Murialdo, D. Ferone

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Somatostatin (SS) receptor scintigraphy is useful for the diagnosis of lesions with high density of SS receptors, and above all neuroendocrine tumors. For several years, only indium-labeled octreotide has been applied to visualise in vivo tissues with SS receptor overexpression. Radiolabeled octreotide became the gold standard for the detection of neuroendocrine tumors. More recently, however, several new SS analogues with varying affinity for SS receptor sub-types have been developed, and different radionuclides as radiolabels have been introduced. Moreover, significant improvements have been made by the introduction of hybrid machines, such as single photon emission computed tomography/computed tomography (SPECT/CT) or positron emission tomography (PET/CT that enable to perform whole-body imaging quickly and with high anatomical resolution in several body areas, including the chest. The development of more specific radiopharmaceuticals, together with the modern technique of imaging, may provide excellent quality images with high contrast, allowing to depict very small lesions and making them easy to interpret. Indeed, in the management of SS receptor-positive lesions, the contribution of nuclear medicine is essential in several clinical settings, such as initial diagnosis, disease staging, follow-up, treatment planning, and treatment monitoring. In addition, the tracer uptake might be used as a prognostic parameter and as a predictor of treatment response. In the chest, apart in (neuro)endocrine tumors, SS receptors have been demonstrated in granulomatous diseases, like sarcoidosis and other immune-mediated disorders, such as anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. In this paper we review and discuss the role of SS receptor scintigraphy in diagnosis, staging or follow-up of thoracic SS receptor-positive lesions.

Original languageEnglish
Pages (from-to)889-902
Number of pages14
JournalJournal of Endocrinological Investigation
Volume30
Issue number10
Publication statusPublished - Nov 2007

Fingerprint

Thoracic Diseases
Somatostatin Receptors
Radionuclide Imaging
Thorax
Neuroendocrine Tumors
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Whole Body Imaging
Octreotide
Radiopharmaceuticals
Nuclear Medicine
Immune System Diseases
Sarcoidosis
Somatostatin
Radioisotopes
Positron-Emission Tomography

Keywords

  • Granulomatous diseases
  • Lung tumors
  • Sarcoidosis
  • Somatostatin receptor scintigraphy
  • Thymoma

ASJC Scopus subject areas

  • Endocrinology

Cite this

Ameril, P., Gatto, F., Arvigo, M., Villa, G., Resmini, E., Minuto, F., ... Ferone, D. (2007). Somatostatin receptor scintigraphy in thoracic diseases. Journal of Endocrinological Investigation, 30(10), 889-902.

Somatostatin receptor scintigraphy in thoracic diseases. / Ameril, P.; Gatto, F.; Arvigo, M.; Villa, G.; Resmini, E.; Minuto, F.; Murialdo, G.; Ferone, D.

In: Journal of Endocrinological Investigation, Vol. 30, No. 10, 11.2007, p. 889-902.

Research output: Contribution to journalArticle

Ameril, P, Gatto, F, Arvigo, M, Villa, G, Resmini, E, Minuto, F, Murialdo, G & Ferone, D 2007, 'Somatostatin receptor scintigraphy in thoracic diseases', Journal of Endocrinological Investigation, vol. 30, no. 10, pp. 889-902.
Ameril P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F et al. Somatostatin receptor scintigraphy in thoracic diseases. Journal of Endocrinological Investigation. 2007 Nov;30(10):889-902.
Ameril, P. ; Gatto, F. ; Arvigo, M. ; Villa, G. ; Resmini, E. ; Minuto, F. ; Murialdo, G. ; Ferone, D. / Somatostatin receptor scintigraphy in thoracic diseases. In: Journal of Endocrinological Investigation. 2007 ; Vol. 30, No. 10. pp. 889-902.
@article{3cd73efd42e74b57a9b68ed48c7966f8,
title = "Somatostatin receptor scintigraphy in thoracic diseases",
abstract = "Somatostatin (SS) receptor scintigraphy is useful for the diagnosis of lesions with high density of SS receptors, and above all neuroendocrine tumors. For several years, only indium-labeled octreotide has been applied to visualise in vivo tissues with SS receptor overexpression. Radiolabeled octreotide became the gold standard for the detection of neuroendocrine tumors. More recently, however, several new SS analogues with varying affinity for SS receptor sub-types have been developed, and different radionuclides as radiolabels have been introduced. Moreover, significant improvements have been made by the introduction of hybrid machines, such as single photon emission computed tomography/computed tomography (SPECT/CT) or positron emission tomography (PET/CT that enable to perform whole-body imaging quickly and with high anatomical resolution in several body areas, including the chest. The development of more specific radiopharmaceuticals, together with the modern technique of imaging, may provide excellent quality images with high contrast, allowing to depict very small lesions and making them easy to interpret. Indeed, in the management of SS receptor-positive lesions, the contribution of nuclear medicine is essential in several clinical settings, such as initial diagnosis, disease staging, follow-up, treatment planning, and treatment monitoring. In addition, the tracer uptake might be used as a prognostic parameter and as a predictor of treatment response. In the chest, apart in (neuro)endocrine tumors, SS receptors have been demonstrated in granulomatous diseases, like sarcoidosis and other immune-mediated disorders, such as anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. In this paper we review and discuss the role of SS receptor scintigraphy in diagnosis, staging or follow-up of thoracic SS receptor-positive lesions.",
keywords = "Granulomatous diseases, Lung tumors, Sarcoidosis, Somatostatin receptor scintigraphy, Thymoma",
author = "P. Ameril and F. Gatto and M. Arvigo and G. Villa and E. Resmini and F. Minuto and G. Murialdo and D. Ferone",
year = "2007",
month = "11",
language = "English",
volume = "30",
pages = "889--902",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "10",

}

TY - JOUR

T1 - Somatostatin receptor scintigraphy in thoracic diseases

AU - Ameril, P.

AU - Gatto, F.

AU - Arvigo, M.

AU - Villa, G.

AU - Resmini, E.

AU - Minuto, F.

AU - Murialdo, G.

AU - Ferone, D.

PY - 2007/11

Y1 - 2007/11

N2 - Somatostatin (SS) receptor scintigraphy is useful for the diagnosis of lesions with high density of SS receptors, and above all neuroendocrine tumors. For several years, only indium-labeled octreotide has been applied to visualise in vivo tissues with SS receptor overexpression. Radiolabeled octreotide became the gold standard for the detection of neuroendocrine tumors. More recently, however, several new SS analogues with varying affinity for SS receptor sub-types have been developed, and different radionuclides as radiolabels have been introduced. Moreover, significant improvements have been made by the introduction of hybrid machines, such as single photon emission computed tomography/computed tomography (SPECT/CT) or positron emission tomography (PET/CT that enable to perform whole-body imaging quickly and with high anatomical resolution in several body areas, including the chest. The development of more specific radiopharmaceuticals, together with the modern technique of imaging, may provide excellent quality images with high contrast, allowing to depict very small lesions and making them easy to interpret. Indeed, in the management of SS receptor-positive lesions, the contribution of nuclear medicine is essential in several clinical settings, such as initial diagnosis, disease staging, follow-up, treatment planning, and treatment monitoring. In addition, the tracer uptake might be used as a prognostic parameter and as a predictor of treatment response. In the chest, apart in (neuro)endocrine tumors, SS receptors have been demonstrated in granulomatous diseases, like sarcoidosis and other immune-mediated disorders, such as anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. In this paper we review and discuss the role of SS receptor scintigraphy in diagnosis, staging or follow-up of thoracic SS receptor-positive lesions.

AB - Somatostatin (SS) receptor scintigraphy is useful for the diagnosis of lesions with high density of SS receptors, and above all neuroendocrine tumors. For several years, only indium-labeled octreotide has been applied to visualise in vivo tissues with SS receptor overexpression. Radiolabeled octreotide became the gold standard for the detection of neuroendocrine tumors. More recently, however, several new SS analogues with varying affinity for SS receptor sub-types have been developed, and different radionuclides as radiolabels have been introduced. Moreover, significant improvements have been made by the introduction of hybrid machines, such as single photon emission computed tomography/computed tomography (SPECT/CT) or positron emission tomography (PET/CT that enable to perform whole-body imaging quickly and with high anatomical resolution in several body areas, including the chest. The development of more specific radiopharmaceuticals, together with the modern technique of imaging, may provide excellent quality images with high contrast, allowing to depict very small lesions and making them easy to interpret. Indeed, in the management of SS receptor-positive lesions, the contribution of nuclear medicine is essential in several clinical settings, such as initial diagnosis, disease staging, follow-up, treatment planning, and treatment monitoring. In addition, the tracer uptake might be used as a prognostic parameter and as a predictor of treatment response. In the chest, apart in (neuro)endocrine tumors, SS receptors have been demonstrated in granulomatous diseases, like sarcoidosis and other immune-mediated disorders, such as anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. In this paper we review and discuss the role of SS receptor scintigraphy in diagnosis, staging or follow-up of thoracic SS receptor-positive lesions.

KW - Granulomatous diseases

KW - Lung tumors

KW - Sarcoidosis

KW - Somatostatin receptor scintigraphy

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=38449096888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449096888&partnerID=8YFLogxK

M3 - Article

C2 - 18075294

AN - SCOPUS:38449096888

VL - 30

SP - 889

EP - 902

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 10

ER -